A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorTianjin Medical University
About this trial
This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease
Eligibility criteria
Qualifiers
Subject is 18 to 70 years of age.
Subjects who do not have previous, active or latent tuberculosis (TB).
Subject must have Vogt-Koyanagi-Harada disease less than one month.
Subject who were previously treated with systemic glucocorticoid less than one week.
Disqualifiers
Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV).
Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.
Subject has previous exposure to anti-tumor necrosis factor (TNF) therapy or any biologic therapy with a potential therapeutic impact on non-infectious uveitis.
Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline visit.
Trial design
Treatments tested in this trial
- Adalimumab
Treatment groups
15 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov